NCT01377987View on ClinicalTrials.gov

Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients

NACompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Heart Failures
Interventions
DRUG

Acetazolamide

4 mg/kg, once daily before bed, for 7 days

DRUG

Placebo

4 mg/kg, once daily before bed, for 7 days

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

American Heart Association

OTHER

collaborator

National Institutes of Health (NIH)

NIH

lead

David Andrew Wellman

OTHER

NCT01377987 - Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients | Biotech Hunter | Biotech Hunter